recombinant cxcl13 (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems recombinant cxcl13
$a , Left, UMAP of LN stromal cells by entity. Right, percentages of rFRCs and rBECs (rLN n = 5, FL n = 6, DLBCL n = 8 patients). b , Differentially expressed genes between rLN-derived ( n = 2,363 cells) and DLBCL-derived ( n = 2,983 cells) FRCs (adjusted P < 0.05, log(fold change) > 0.5). c , Homeostatic (top) and inflammatory (bottom) chemokine expression in bulk data . d , Pearson correlation of <t>CXCL13</t> expression and CIBERSORTx-derived FDC fractions. e , CXCL13 plasma protein levels in FL ( n = 18 patients) and DLBCL ( n = 22 patients). Vertical lines indicate the mean per entity. f , Exemplary rLN and DLBCL mIF images, representative of n = 4 patients per entity. Scale bar, 50 μm. Dashed circles: CD21+ regions. g , mIF-derived CXCL13 and CXCR5 signals averaged across four adjacent pairs of CD21 + follicular and CD21 − extrafollicular regions per sample. h , i , Spatial transcriptomics plots of FL-LN ( h ) and DLBCL-LN ( i ) cores colored by cell type and CXCL13 – CXCR5 ligand–receptor (L–R) score. j , mIF-derived enrichment of CXCL13 + cells per cell type in DLBCL versus rLN/FL samples. Asterisks indicate P < 0.01; exact P values are provided in the source data. k , CXCL13 expression in CD8 + T cells ( n = 21,268 cells) . l , Percentage of CXCR5 + cells within CD3 − fractions measured by flow cytometry (rLN n = 7, FL n = 24, DLBCL n = 18 patients). m , Migrated rLN- and DLBCL-derived B cells in the Transwell assay (mean ± s.d., n = 3 patients per condition). For c and d : tonsil n = 10, FL 1/2/3A n = 145, FL 3B n = 48, DLBCL n = 430 patients. For f , g and j : rLN n = 4, FL n = 5, DLBCL n = 4 patients. P values in a , c , e , g and l : two-sided Wilcoxon rank-sum test. P value in m : two-sided unpaired Welch’s t test. P values in j : two-sided Fisher’s exact test. P values in c , g and j were adjusted using the Benjamini–Hochberg method. Box plots: center line, median; box, interquartile range; whiskers, 1.5× the interquartile range; points, data values. FC, fold change; T tox EM, effector memory cytotoxic T cells; hr, human recombinant.$
Recombinant Cxcl13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+st+sequencing/pmc13035477-316-30-35?v=R%26D+Systems
Average 94 stars, based on 4 article reviews

recombinant cxcl13 - by Bioz Stars, 2026-08

94/100 stars

Images

1) Product Images from "Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma"

Article Title: Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma

Journal: Nature Cancer

doi: 10.1038/s43018-026-01136-z

$a , Left, UMAP of LN stromal cells by entity. Right, percentages of rFRCs and rBECs (rLN n = 5, FL n = 6, DLBCL n = 8 patients). b , Differentially expressed genes between rLN-derived ( n = 2,363 cells) and DLBCL-derived ( n = 2,983 cells) FRCs (adjusted P < 0.05, log(fold change) > 0.5). c , Homeostatic (top) and inflammatory (bottom) chemokine expression in bulk data . d , Pearson correlation of CXCL13 expression and CIBERSORTx-derived FDC fractions. e , CXCL13 plasma protein levels in FL ( n = 18 patients) and DLBCL ( n = 22 patients). Vertical lines indicate the mean per entity. f , Exemplary rLN and DLBCL mIF images, representative of n = 4 patients per entity. Scale bar, 50 μm. Dashed circles: CD21+ regions. g , mIF-derived CXCL13 and CXCR5 signals averaged across four adjacent pairs of CD21 + follicular and CD21 − extrafollicular regions per sample. h , i , Spatial transcriptomics plots of FL-LN ( h ) and DLBCL-LN ( i ) cores colored by cell type and CXCL13 – CXCR5 ligand–receptor (L–R) score. j , mIF-derived enrichment of CXCL13 + cells per cell type in DLBCL versus rLN/FL samples. Asterisks indicate P < 0.01; exact P values are provided in the source data. k , CXCL13 expression in CD8 + T cells ( n = 21,268 cells) . l , Percentage of CXCR5 + cells within CD3 − fractions measured by flow cytometry (rLN n = 7, FL n = 24, DLBCL n = 18 patients). m , Migrated rLN- and DLBCL-derived B cells in the Transwell assay (mean ± s.d., n = 3 patients per condition). For c and d : tonsil n = 10, FL 1/2/3A n = 145, FL 3B n = 48, DLBCL n = 430 patients. For f , g and j : rLN n = 4, FL n = 5, DLBCL n = 4 patients. P values in a , c , e , g and l : two-sided Wilcoxon rank-sum test. P value in m : two-sided unpaired Welch’s t test. P values in j : two-sided Fisher’s exact test. P values in c , g and j were adjusted using the Benjamini–Hochberg method. Box plots: center line, median; box, interquartile range; whiskers, 1.5× the interquartile range; points, data values. FC, fold change; T tox EM, effector memory cytotoxic T cells; hr, human recombinant.$
Figure Legend Snippet: a , Left, UMAP of LN stromal cells by entity. Right, percentages of rFRCs and rBECs (rLN n = 5, FL n = 6, DLBCL n = 8 patients). b , Differentially expressed genes between rLN-derived ( n = 2,363 cells) and DLBCL-derived ( n = 2,983 cells) FRCs (adjusted P < 0.05, log(fold change) > 0.5). c , Homeostatic (top) and inflammatory (bottom) chemokine expression in bulk data . d , Pearson correlation of CXCL13 expression and CIBERSORTx-derived FDC fractions. e , CXCL13 plasma protein levels in FL ( n = 18 patients) and DLBCL ( n = 22 patients). Vertical lines indicate the mean per entity. f , Exemplary rLN and DLBCL mIF images, representative of n = 4 patients per entity. Scale bar, 50 μm. Dashed circles: CD21+ regions. g , mIF-derived CXCL13 and CXCR5 signals averaged across four adjacent pairs of CD21 + follicular and CD21 − extrafollicular regions per sample. h , i , Spatial transcriptomics plots of FL-LN ( h ) and DLBCL-LN ( i ) cores colored by cell type and CXCL13 – CXCR5 ligand–receptor (L–R) score. j , mIF-derived enrichment of CXCL13 + cells per cell type in DLBCL versus rLN/FL samples. Asterisks indicate P < 0.01; exact P values are provided in the source data. k , CXCL13 expression in CD8 + T cells ( n = 21,268 cells) . l , Percentage of CXCR5 + cells within CD3 − fractions measured by flow cytometry (rLN n = 7, FL n = 24, DLBCL n = 18 patients). m , Migrated rLN- and DLBCL-derived B cells in the Transwell assay (mean ± s.d., n = 3 patients per condition). For c and d : tonsil n = 10, FL 1/2/3A n = 145, FL 3B n = 48, DLBCL n = 430 patients. For f , g and j : rLN n = 4, FL n = 5, DLBCL n = 4 patients. P values in a , c , e , g and l : two-sided Wilcoxon rank-sum test. P value in m : two-sided unpaired Welch’s t test. P values in j : two-sided Fisher’s exact test. P values in c , g and j were adjusted using the Benjamini–Hochberg method. Box plots: center line, median; box, interquartile range; whiskers, 1.5× the interquartile range; points, data values. FC, fold change; T tox EM, effector memory cytotoxic T cells; hr, human recombinant.

Techniques Used: Derivative Assay, Expressing, Clinical Proteomics, Spatial Transcriptomics, Flow Cytometry, Transwell Assay, Recombinant

$( A ) Heatmap showing estimated cell type fractions as determined using CIBERSORTx (CSx) within a large bulk transcriptomics dataset . ( B ) Box plots depicting CSx fractions of exemplary cell types across disease entities. Boxes indicate the median (center line), interquartile range (bounds) and 1.5x interquartile range (whiskers). Data points represent patient samples. P-values were calculated using two-sided unpaired Welch’s t-test and adjusted according to Benjamini-Hochberg. ( C ) Dot plot showing Spearman correlation coefficients of chemokine expression and cell type fractions. Dot sizes represent -log10 FDR-adjusted p-value of correlation tests. ( D ) Scatter plots color-coded by disease entity correlating CXCL12 (left panel) and CCL21 (right panel) expression with CSx-derived FRC factions. P-values were calculated using Pearson correlation. ( E , F ) Bulk RNA-seq datasets , stratified by FDC abundance into high and low samples using maximally selected rank statistics based on CSx fractions, represented in a Kaplan-Meier curve showing overall survival (left panels; log-rank test) and scatter plot of FDC fractions and CXCL13 expression (right panels; Pearson correlation). T PR =T prol . For panels A – D : tonsil n = 10; FL 1/2/3 A n = 145; FL 3B n = 48; DLBCL n = 430 patients. For panel E : FDC-high n = 61; FDC-low n = 44 patients. For panel F : FDC-high n = 302; FDC-low n = 68 patients.$
Figure Legend Snippet: ( A ) Heatmap showing estimated cell type fractions as determined using CIBERSORTx (CSx) within a large bulk transcriptomics dataset . ( B ) Box plots depicting CSx fractions of exemplary cell types across disease entities. Boxes indicate the median (center line), interquartile range (bounds) and 1.5x interquartile range (whiskers). Data points represent patient samples. P-values were calculated using two-sided unpaired Welch’s t-test and adjusted according to Benjamini-Hochberg. ( C ) Dot plot showing Spearman correlation coefficients of chemokine expression and cell type fractions. Dot sizes represent -log10 FDR-adjusted p-value of correlation tests. ( D ) Scatter plots color-coded by disease entity correlating CXCL12 (left panel) and CCL21 (right panel) expression with CSx-derived FRC factions. P-values were calculated using Pearson correlation. ( E , F ) Bulk RNA-seq datasets , stratified by FDC abundance into high and low samples using maximally selected rank statistics based on CSx fractions, represented in a Kaplan-Meier curve showing overall survival (left panels; log-rank test) and scatter plot of FDC fractions and CXCL13 expression (right panels; Pearson correlation). T PR =T prol . For panels A – D : tonsil n = 10; FL 1/2/3 A n = 145; FL 3B n = 48; DLBCL n = 430 patients. For panel E : FDC-high n = 61; FDC-low n = 44 patients. For panel F : FDC-high n = 302; FDC-low n = 68 patients.

Techniques Used: Transcriptomics, Expressing, Derivative Assay, RNA Sequencing

$( A ) Representative triangle-thresholded mIF images showing CD21 (top panels) as well as CXCL13 (bottom panels) signal in rLN (n = 4), FL (n = 5) and DLBCL (n = 4) patient samples. Scale bar indicates 50μm. ( B ) UMAP representation of spatial transcriptomics data colored by cell type (color code depicted in panel C ). ( C ) Heatmap showing scaled expression of key marker gene expression as well chemokines. ( D ) Stacked bar plot of FDC/FRC/rFRC fractions (top panel) and violin plot of CXCL13 expression in these subsets (bottom panel). ( E ) Spatial transcriptomics plots of FL (left panels) and DLBCL (right panels) tissue cores colored by cell type (left panels) alongside magnified views of chemokine expression. ( F ) Heatmap showing scaled expression of key T cell markers across CD8 + T cell populations as measured using mIF. ( G ) Box plot showing per-sample percentage of CXCL13 + cells (as determined using Otsu thresholding) among PD1 + CD8 + effector memory T cells in the mIF dataset. Boxes indicate the median (center line), interquartile range (bounds) and 1.5x interquartile range (whiskers). Data points represent patient samples. P-values were calculated using a two-sided unpaired Welch’s t-test. ( H ) Spearman correlation coefficients of key T cell markers across all CD8 + T cell populations (n = 21,268 cells). ( I ) Volcano plot showing differentially expressed genes comparing PD1 + CD8 + effector memory T cell populations (T TOX EM-II n = 2,018; T TOX EM-III n = 9,208 cells). Labels indicate cluster-identifying genes as well as CXCL13 . Abbreviations: T TOX EM = effector memory cytotoxic T cells. For panels A , F , G : rLN n = 4; FL n = 5; DLBCL n = 4 patients. For panels B – E : FL n = 1; DLBCL n = 1 patient.$
Figure Legend Snippet: ( A ) Representative triangle-thresholded mIF images showing CD21 (top panels) as well as CXCL13 (bottom panels) signal in rLN (n = 4), FL (n = 5) and DLBCL (n = 4) patient samples. Scale bar indicates 50μm. ( B ) UMAP representation of spatial transcriptomics data colored by cell type (color code depicted in panel C ). ( C ) Heatmap showing scaled expression of key marker gene expression as well chemokines. ( D ) Stacked bar plot of FDC/FRC/rFRC fractions (top panel) and violin plot of CXCL13 expression in these subsets (bottom panel). ( E ) Spatial transcriptomics plots of FL (left panels) and DLBCL (right panels) tissue cores colored by cell type (left panels) alongside magnified views of chemokine expression. ( F ) Heatmap showing scaled expression of key T cell markers across CD8 + T cell populations as measured using mIF. ( G ) Box plot showing per-sample percentage of CXCL13 + cells (as determined using Otsu thresholding) among PD1 + CD8 + effector memory T cells in the mIF dataset. Boxes indicate the median (center line), interquartile range (bounds) and 1.5x interquartile range (whiskers). Data points represent patient samples. P-values were calculated using a two-sided unpaired Welch’s t-test. ( H ) Spearman correlation coefficients of key T cell markers across all CD8 + T cell populations (n = 21,268 cells). ( I ) Volcano plot showing differentially expressed genes comparing PD1 + CD8 + effector memory T cell populations (T TOX EM-II n = 2,018; T TOX EM-III n = 9,208 cells). Labels indicate cluster-identifying genes as well as CXCL13 . Abbreviations: T TOX EM = effector memory cytotoxic T cells. For panels A , F , G : rLN n = 4; FL n = 5; DLBCL n = 4 patients. For panels B – E : FL n = 1; DLBCL n = 1 patient.

Techniques Used: Spatial Transcriptomics, Expressing, Marker, Gene Expression

$a , UMAP representation of a microarray dataset with homeostatic ( CXCL12 , CXCL13 , CCL19 , CCL21 ) and inflammatory ( CXCL9 , CXCL10 , CXCL11 ) chemokine expression values used as features for dimensionality reduction. Left, UMAP displaying pie charts (within each dot) that represent the k = 20 nearest neighbors, colored according to disease entity. Right, the same UMAP colored according to the mean expression of homeostatic (top) and inflammatory (bottom) chemokines. b , Bulk RNA-seq dataset stratified according to homeostatic chemokine expression into high ( n = 519 patients) and low ( n = 99 patients) groups using maximally selected rank statistics, shown as a dot plot (top) and a Kaplan–Meier curve of overall survival (bottom). The P value was calculated using the log-rank test. c , Forest plot summarizing log 10 -transformed hazard ratios (center), 95% confidence intervals (error bars) and Wald-derived P values estimated from univariate Cox proportional hazards models assessing the association between homeostatic chemokine expression and overall survival across five individual DLBCL bulk datasets , – . d , Same UMAP as in a , colored by CIBERSORTx-derived FDC fractions. e , Bulk RNA-seq dataset stratified by FDC abundance into high ( n = 255 patients) and low ( n = 364 patients) groups using maximally selected rank statistics based on CIBERSORTx fractions, shown as a Kaplan–Meier curve of overall survival (left; log-rank test) and a scatter plot of log-transformed FDC fractions and CXCL13 expression (right; Pearson correlation). f , Forest plot summarizing log 10 -transformed hazard ratios (center), 95% confidence intervals (error bars) and Wald-derived P values estimated from Cox proportional hazards models assessing the association between FDC fraction and overall survival across five individual DLBCL bulk datasets , – . For panels a and d : tonsil n = 10, FL 1/2/3A n = 145, FL 3B n = 48 and DLBCL n = 430 patients. OS, overall survival; HR, hazard ratio.$
Figure Legend Snippet: a , UMAP representation of a microarray dataset with homeostatic ( CXCL12 , CXCL13 , CCL19 , CCL21 ) and inflammatory ( CXCL9 , CXCL10 , CXCL11 ) chemokine expression values used as features for dimensionality reduction. Left, UMAP displaying pie charts (within each dot) that represent the k = 20 nearest neighbors, colored according to disease entity. Right, the same UMAP colored according to the mean expression of homeostatic (top) and inflammatory (bottom) chemokines. b , Bulk RNA-seq dataset stratified according to homeostatic chemokine expression into high ( n = 519 patients) and low ( n = 99 patients) groups using maximally selected rank statistics, shown as a dot plot (top) and a Kaplan–Meier curve of overall survival (bottom). The P value was calculated using the log-rank test. c , Forest plot summarizing log 10 -transformed hazard ratios (center), 95% confidence intervals (error bars) and Wald-derived P values estimated from univariate Cox proportional hazards models assessing the association between homeostatic chemokine expression and overall survival across five individual DLBCL bulk datasets , – . d , Same UMAP as in a , colored by CIBERSORTx-derived FDC fractions. e , Bulk RNA-seq dataset stratified by FDC abundance into high ( n = 255 patients) and low ( n = 364 patients) groups using maximally selected rank statistics based on CIBERSORTx fractions, shown as a Kaplan–Meier curve of overall survival (left; log-rank test) and a scatter plot of log-transformed FDC fractions and CXCL13 expression (right; Pearson correlation). f , Forest plot summarizing log 10 -transformed hazard ratios (center), 95% confidence intervals (error bars) and Wald-derived P values estimated from Cox proportional hazards models assessing the association between FDC fraction and overall survival across five individual DLBCL bulk datasets , – . For panels a and d : tonsil n = 10, FL 1/2/3A n = 145, FL 3B n = 48 and DLBCL n = 430 patients. OS, overall survival; HR, hazard ratio.

Techniques Used: Microarray, Expressing, RNA Sequencing, Transformation Assay, Derivative Assay

Review

recombinant cxcl13 (R&D Systems)

Structured Review

Images

1) Product Images from "Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma"

Similar Products

Image Search Results